Abstract

The authors performed a cross-sectional analysis to evaluate the association between arsenic exposure from drinking water and blood pressure using baseline data of 10,910 participants in the Health Effects of Arsenic Longitudinal Study in Bangladesh (October 2000–May 2002). A time-weighted well arsenic concentration (TWA) based on current and past use of drinking wells was derived. Odds ratios for high pulse pressure (≥55 mmHg) by increasing TWA quintiles (≤8, 8.1–40.8, 40.9–91.0, 91.1–176.0, and 176.1–864.0 μg/liter) were 1.00 (referent), 1.39 (95% confidence interval (CI): 1.14, 1.71), 1.21 (95% CI: 0.99, 1.49), 1.19 (95% CI: 0.97, 1.45), and 1.19 (95% CI: 0.97, 1.46). Among participants with a lower than average dietary intake level of B vitamins and folate, the odds ratios for high pulse pressure by increasing TWA quintiles were 1.00 (referent), 1.84 (95% CI: 1.07, 3.16), 1.89 (95% CI: 1.11, 3.20), 1.83 (95% CI: 1.09, 3.07), and 1.89 (95% CI: 1.12, 3.20). The odds ratios for systolic hypertension suggest a similar but weaker association. No apparent associations were observed between TWA and general or diastolic hypertension. These findings indicate that the effect of low-level arsenic exposure on blood pressure is nonlinear and may be more pronounced in persons with lower intake of nutrients related to arsenic metabolism and cardiovascular health. Future research is needed to evaluate the effect of low-level arsenic exposure on specific cardiovascular outcomes.

Epidemiologic studies have associated high-level arsenic exposure from drinking water (average level, >300 μg/liter) with elevated risks of vascular diseases, including peripheral vascular diseases (1), blackfoot disease (2), hypertension (3, 4), ischemic heart disease (5, 6), cerebrovascular disease (7), and carotid atheroslerosis (8). However, little is known about the associations between low-level arsenic exposure from drinking water (<100 μg/liter or <50 μg/liter) and vascular diseases, partly because of lack of detailed and reliable individual-level data on exposure and/or outcome (9).

The elevated groundwater arsenic concentration in Bangladesh has raised major public health concerns. More than 50 million people have been chronically exposed to drinking water with arsenic concentrations exceeding the World Health Organization standard (10 μg/liter) (10). The Health Effects of Arsenic Longitudinal Study was established to evaluate the health effects of arsenic exposure in a rural Bangladeshi population. Specifically, the large variation in arsenic exposure among study participants provides a unique opportunity to evaluate the health effects of arsenic exposure in dose ranges that are relevant to millions of people in many parts of the world, including the United States (11, 12).

Hypertension, or high blood pressure, is the chronic state of elevated pressure in the arteries. Prospective large epidemiologic studies have unequivocally demonstrated a strong, direct relation between high blood pressure and mortality from cardiovascular diseases (13). Blood pressure has two components: Systolic blood pressure (SBP) is measured while the heart contracts and pumps blood into the arteries, and diastolic blood pressure (DBP) is measured while the heart fills with blood. Previous studies of arsenic exposure and blood pressure are limited in that they were conducted in populations with very high arsenic exposure and that they only assessed the risk of general hypertension, defined as having a SBP of ≥140 mmHg and/or a DBP of ≥90 mmHg (14, 15). However, besides general hypertension, several dimensions of blood pressure have been associated with an increased risk of vascular disease. Clinic-based measurements that predict vascular disease include SBP, DBP, mean arterial pressure (defined as ⅓ × (SBP + 2 × DBP)), and pulse pressure (the difference between SBP and DBP) (16–18).

In addition, previous studies did not address the potential of interindividual variability in susceptibility to the adverse effect of arsenic exposure on blood pressure. The methylation of arsenic results in the production of homocysteine (19, 20). Higher levels of plasma homocysteine have been associated with high blood pressure (21, 22). Because the metabolism of homocysteine requires sufficient levels of vitamins B2, B12, and B6 and folic acid (23), arsenic exposure may affect blood pressure through its effect on the formation of homocysteine, especially in a background of inadequate intake of folate and B vitamins. In this study, we evaluated the association between arsenic exposure and blood pressure in a population with a wide range of low-level arsenic exposure from drinking water. We also examined the potential modification by dietary intakes of folate and B vitamins.

MATERIALS AND METHODS

Study population

The parent study (Health Effects of Arsenic Longitudinal Study) is an ongoing, prospective cohort study in Araihazar, Bangladesh. Details of the study methodologies have been presented elsewhere (24, 25). Briefly, prior to recruitment of subjects, water samples and geographic positional system data were collected for a set of 5,966 contiguous wells in a well-defined geographic area of 25 km2 in Araihazar. Well owners were interviewed to create a roster list of 65,876 regular well users and residents in the area. Eligibility criteria for the cohort study included the following: being married (in order to increase stability of residence), being aged 18 years or more, and having had resided in the study area for 5 or more years (24). Between October 22, 2000, and May 19, 2002, 14,828 potential participants meeting the eligibility criteria were identified from the roster list. Nineteen percent of those eligible (n = 2,778) were not at home during study visits. Of the 12,050 who were available and approached, 11,746 (97.5 percent response rate) participated (24). Verbal consent was obtained from all the participants. The study procedures were approved by the Columbia University Institutional Review Board and the Ethical Committee of the Bangladesh Medical Research Council.

Information on patterns and history of well use, demographics, lifestyle characteristics, and dietary intakes was collected in an extensive baseline interview. Trained physicians completed a comprehensive physical examination that included blood pressure measurements. Both interviewers and physicians were blind to the well arsenic concentration until all the interviews and physical examinations were completed.

Measurements of nutritional intakes

Dietary intakes were measured at baseline by use of a semiquantitative food frequency questionnaire that was designed for the study population. Details of the food frequency questionnaire and a validation study of the food frequency questionnaire have been described elsewhere (26). In the validation study of the food frequency questionnaire, correlations between average daily consumptions measured by the food frequency questionnaire and those measured by two 7-day food diaries indicated that the validity of the food frequency questionnaire in measuring long-term intakes of the nutrients of interest in the present study was moderately good. Correlations for vitamins B2, B6, and B12 and folate were 0.37, 0.39, 0.57, and 0.30, respectively (26). We used both the US Department of Agriculture Nutrient Database for Standard Reference (abbreviated version) (27) and the Indian food nutrient database (28) to convert food item intakes to nutrient intake values. All intakes were adjusted for total energy intake using the residual method (29).

Blood pressure measurements

Blood pressure was measured by trained clinicians using an automatic sphygmomanometer (HEM 712-C; Omron Healthcare GmbH, Hamburg, Germany). This model has been validated to have 85 percent of readings falling within 5–10 mmHg of the mercury standard (30). We used an automated sphygmomanometer because it is portable, easy to use, and less prone to observer bias. These strengths are especially important because our fieldwork was conducted in a rural area. Measurements were taken with participants in a seated position after 5 minutes of rest, with the cuff around the upper left arm, in accordance with recommended guidelines.

To reduce false positive measurements of high blood pressure due to the transient stress response to medical professionals (“white coat hypertension”), two additional measurements were taken after 2–3 minutes of rest for respondents found to have a SBP of ≥140 mmHg and/or a DBP of ≥90 mmHg at the first measurement, and the measurement with the lowest blood pressure was recorded.

A reliability study of blood pressure measurements was conducted in 61 subjects with three measurements taken regardless of blood pressure levels at the first measurement. Intraclass correlation coefficients were computed for SBP and DBP separately to evaluate the correlations among the three measurements. The reliability of blood pressure measurement was good, with all intraclass correlation coefficients between 0.92 and 0.94. The absolute differences among measurements were 0.9–2.0 and 0.7–2.8 mmHg for SBP and DBP, respectively.

Information on medicine use was extracted from the questionnaires. Study participants were asked to show all medicines they were taking regularly, and the interviewers recorded generic names. A total of 110 participants were taking antihypertension medicines at the time of baseline interview.

Arsenic exposure measurements

Water samples from the 5,966 wells were collected in 50-ml acid-washed tubes after pumping the well for 5 minutes. The arsenic concentration was measured with graphite furnace atomic-absorption spectrometry with a Hitachi Z-8200 system (Hitachi, Tokyo, Japan) (31). Samples that fell below the detection limit (5 μg/liter) were subsequently analyzed by inductively coupled plasma mass spectrometry, with a detection limit of 0.1 μg/liter. Consistent with similar analysis conducted in other parts of the world (32), analysis for time-series samples from 20 tube wells in the study area showed that well arsenic concentrations were stable over 3 years (33). In addition to information on current well use, participants were also asked about the exact location and duration of use of the previous well. Often the participant led the interviewer to the previous well. Questions were asked of husbands and wives separately, and if the history in a married couple was not the same, participants were asked to give a reason. We derived a time-weighted well arsenic concentration (TWA) as a function of drinking durations and well arsenic concentrations (TWA (μg/liter) = ∑ CiTi / ∑ Ti, where Ci and Ti denote the well arsenic concentration and drinking duration for the ith well) (34). The average time for which the arsenic concentration was known was 10.0 years for men and 8.3 years for women, accounting for 25 percent of participants' lifetime, on average, for both sexes.

Statistical methods

We first conducted descriptive analysis to assess differences in blood pressure by levels of demographics and arsenic exposure measures. To account for the correlation of arsenic exposure among participants who consumed water from the same well, we performed linear and logistic regression modeling of clustered data using generalized estimating equations (35). Robust variance estimates were used to calculate standard errors and confidence intervals.

Previous studies suggested a dose-response relation between hypertension and high levels of arsenic exposure. We first evaluated the associations of arsenic exposure with SBP, DBP, mean arterial pressure (⅓ × (SBP + 2 × DBP)), and pulse pressure (SBP − DBP) in linear regression models. Since results did not suggest any linearity of the associations, adjusted odds ratios for general hypertension (SBP, ≥140 mmHg, and/or DBP, ≥90 mmHg (14, 15)), systolic hypertension (SBP, ≥140 mmHg), diastolic hypertension (DBP, ≥90 mmHg), and high pulse pressure (SBP − DBP, ≥55 mmHg) in relation to quintiles of TWA were estimated by use of logistic regression models. High pulse pressure was defined as pulse pressure of ≥55 mmHg, the upper 10th percentile of the population distribution. A pulse pressure of ≥55 mmHg has also been studied as a predictor of cardiovascular diseases (36). Our previous analysis suggested that age, sex, body mass index, tobacco smoking status, water consumption, and markers of socioeconomic status such as educational level may modify arsenic toxicity (34, 37). Theses factors, except for water consumption, were also strong predictors of blood pressure. The final models included all the potential confounders in theory.

Potential effect modification by dietary intakes of vitamins B2, B6, and B12 and folate was examined by stratified analysis. Total energy intake was additionally entered in the model as suggested by Willett and Stampfer (29). In addition, a score of 0 or 1 was assigned to participants with less than or greater than or equal to the median intake level of each nutrient, respectively. A composite measure was then created by summing the four individual scores. To formally test whether the association between arsenic exposure and blood pressure differs by levels of nutritional factors, we included cross-product terms representing products of nutrient intake levels and arsenic exposure expressed as a continuous variable in multivariate logistic models.

Among the overall 11,746 participants in the parent cohort study, a total of 11,458 participants with blood pressure measurements were included in descriptive analysis. Participants with available blood pressure measurements did not differ appreciably from those without a blood pressure measurement with respect to demographic and lifestyle attributes (data not shown). Multivariate analysis excluded participants who were taking antihypertension medicines at the time of interview (n = 110) and included 10,910 participants with information on TWA and all the covariate variables. Those with missing intake values on any of the food items in the food frequency questionnaire (n = 296) were further excluded from the stratified analysis by nutritional factors. All analyses were also performed in a subpopulation of 7,960 with a known well arsenic level for ≥5 years (mean, 11.2 years). Sensitivity analysis was also conducted with ≥3 and ≥7 years to define the subpopulation. Results were similar and therefore were not shown. All analyses were conducted using SAS, version 8.0, statistical software (SAS Institute, Inc., Cary, North Carolina).

RESULTS

All of the blood pressure parameters were positively related to age. SBP, DBP, and the mean arterial pressure were positively associated with body mass index and educational attainment, while pulse pressure varied little by these factors (table 1). Compared with never smokers, current smokers and past smokers had lower blood pressure and higher blood pressure, respectively. This finding is in line with findings reported in the literature that cross-sectional studies often observe a transient effect of smoking on blood pressure (38).

TABLE 1.

Mean values of systolic blood pressure, diastolic blood pressure, and pulse pressure in the study population, Araihazar, Bangladesh, October 2000–May 2002

Overall (n = 11,458)SBP*DBP*Combination of SBP and DBP
Pulse blood pressureMeans of mean arterial pressure§General hypertension (%)
No.%Mean TWA* (μg/liter)Mean (mmHg)Systolic hypertension (SBP, ≥140 mmHg) (%)Mean (mmHg)Diastolic hypertension (DBP, ≥90 mmHg) (%)Mean (mmHg)High pulse pressure (DBP, ≥90 mmHg) (%)
Gender
    Female6,55257.2100.0114.17.874.19.839.99.687.413.1
    Male4,90642.899.8115.78.973.79.042.012.487.713.6
Age (years)
    <302,88725.299.8111.53.971.96.539.67.885.18.6
    30–394,03835.299.4113.66.273.98.739.77.587.111.3
    40–492,94125.799.7115.79.674.910.940.811.088.514.8
    50–591,34011.7100.6121.018.075.913.645.122.290.922.8
    ≥602522.2108.4126.425.977.116.649.333.593.630.6
BMI* (tertiles)
    <18.083,76033.0104.8111.15.770.35.340.810.583.98.4
    18.08–20.473,75733.0101.3113.86.373.07.140.810.186.610.2
    >20.473,87134.094.1119.212.778.415.740.811.792.020.9
    Unknown70
Education (years)
    No5,08944.499.0114.27.873.07.941.211.886.712.2
    <63,39229.6102.7114.17.273.59.040.59.987.112.0
    6–91,71415.0102.4115.18.875.010.540.29.688.413.9
    ≥101,25711.092.7118.312.477.615.740.710.791.120.3
    Unknown6
Tobacco smoking
    Nonsmoker7,39464.6100.6114.67.974.510.340.210.087.913.7
    Past smoker7556.6107.4118.814.375.411.443.417.189.918.7
    Current light smoker1,95917.198.5114.78.472.87.741.911.686.812.2
    Current heavy smoker1,33911.793.7113.26.871.96.441.310.685.79.9
    Unknown11
Contraceptive use (in women)
    No4,86674.3101.1113.86.573.99.939.97.787.411.9
    Yes#1,68625.796.8114.88.274.99.440.010.388.213.4
Occupation
    Daily contract laborer4206.7102.8111.75.570.13.641.69.184.07.4
    Factory worker1,14610.0100.4113.04.971.44.841.510.885.38.3
    Farmer (with own land)6886.0111.9115.39.572.87.742.514.387.011.7
    Other paid job4293.792.7119.714.177.214.442.513.091.321.0
    Small business owner/employee1,81715.992.0116.59.275.611.641.010.889.215.6
    Unemployed2362.1110.0125.325.977.619.347.729.593.532.6
    Housemaker6,16753.8100.7114.17.874.29.840.09.787.513.2
    Others5554.899.4113.16.971.86.541.210.085.69.6
TWA (μg/liter)**
    0.1–8.02,29320.52.8114.47.774.510.639.818.387.814.1
    8.1–40.82,14719.423.1115.59.273.89.241.721.687.713.6
    40.9–91.02,22520.363.8115.38.574.39.841.220.487.913.8
    91.1–176.02,21819.9128.2114.58.574.18.840.419.787.512.5
    176.1–864.02,21419.9282.8114.58.073.39.141.220.187.113.1
Overall (n = 11,458)SBP*DBP*Combination of SBP and DBP
Pulse blood pressureMeans of mean arterial pressure§General hypertension (%)
No.%Mean TWA* (μg/liter)Mean (mmHg)Systolic hypertension (SBP, ≥140 mmHg) (%)Mean (mmHg)Diastolic hypertension (DBP, ≥90 mmHg) (%)Mean (mmHg)High pulse pressure (DBP, ≥90 mmHg) (%)
Gender
    Female6,55257.2100.0114.17.874.19.839.99.687.413.1
    Male4,90642.899.8115.78.973.79.042.012.487.713.6
Age (years)
    <302,88725.299.8111.53.971.96.539.67.885.18.6
    30–394,03835.299.4113.66.273.98.739.77.587.111.3
    40–492,94125.799.7115.79.674.910.940.811.088.514.8
    50–591,34011.7100.6121.018.075.913.645.122.290.922.8
    ≥602522.2108.4126.425.977.116.649.333.593.630.6
BMI* (tertiles)
    <18.083,76033.0104.8111.15.770.35.340.810.583.98.4
    18.08–20.473,75733.0101.3113.86.373.07.140.810.186.610.2
    >20.473,87134.094.1119.212.778.415.740.811.792.020.9
    Unknown70
Education (years)
    No5,08944.499.0114.27.873.07.941.211.886.712.2
    <63,39229.6102.7114.17.273.59.040.59.987.112.0
    6–91,71415.0102.4115.18.875.010.540.29.688.413.9
    ≥101,25711.092.7118.312.477.615.740.710.791.120.3
    Unknown6
Tobacco smoking
    Nonsmoker7,39464.6100.6114.67.974.510.340.210.087.913.7
    Past smoker7556.6107.4118.814.375.411.443.417.189.918.7
    Current light smoker1,95917.198.5114.78.472.87.741.911.686.812.2
    Current heavy smoker1,33911.793.7113.26.871.96.441.310.685.79.9
    Unknown11
Contraceptive use (in women)
    No4,86674.3101.1113.86.573.99.939.97.787.411.9
    Yes#1,68625.796.8114.88.274.99.440.010.388.213.4
Occupation
    Daily contract laborer4206.7102.8111.75.570.13.641.69.184.07.4
    Factory worker1,14610.0100.4113.04.971.44.841.510.885.38.3
    Farmer (with own land)6886.0111.9115.39.572.87.742.514.387.011.7
    Other paid job4293.792.7119.714.177.214.442.513.091.321.0
    Small business owner/employee1,81715.992.0116.59.275.611.641.010.889.215.6
    Unemployed2362.1110.0125.325.977.619.347.729.593.532.6
    Housemaker6,16753.8100.7114.17.874.29.840.09.787.513.2
    Others5554.899.4113.16.971.86.541.210.085.69.6
TWA (μg/liter)**
    0.1–8.02,29320.52.8114.47.774.510.639.818.387.814.1
    8.1–40.82,14719.423.1115.59.273.89.241.721.687.713.6
    40.9–91.02,22520.363.8115.38.574.39.841.220.487.913.8
    91.1–176.02,21819.9128.2114.58.574.18.840.419.787.512.5
    176.1–864.02,21419.9282.8114.58.073.39.141.220.187.113.1
*

SBP, systolic blood pressure; DBP, diastolic blood pressure; TWA, time-weighted well arsenic concentration; BMI, body mass index.

Prevalence by category.

Pulse pressure was defined as SBP − DBP.

§

Mean arterial pressure was defined as (⅓ × (SBP + 2 × DBP)).

The median number of cigarettes per day among current smokers was used to classifiy light and heavy smokers.

#

Current use of contraceptive is defined as using any types of contraceptives, including oral contraceptive, contraceptive implant, and the injectable contraceptive.

**

Cutpoints were determined by quintiles of overall study population.

TABLE 1.

Mean values of systolic blood pressure, diastolic blood pressure, and pulse pressure in the study population, Araihazar, Bangladesh, October 2000–May 2002

Overall (n = 11,458)SBP*DBP*Combination of SBP and DBP
Pulse blood pressureMeans of mean arterial pressure§General hypertension (%)
No.%Mean TWA* (μg/liter)Mean (mmHg)Systolic hypertension (SBP, ≥140 mmHg) (%)Mean (mmHg)Diastolic hypertension (DBP, ≥90 mmHg) (%)Mean (mmHg)High pulse pressure (DBP, ≥90 mmHg) (%)
Gender
    Female6,55257.2100.0114.17.874.19.839.99.687.413.1
    Male4,90642.899.8115.78.973.79.042.012.487.713.6
Age (years)
    <302,88725.299.8111.53.971.96.539.67.885.18.6
    30–394,03835.299.4113.66.273.98.739.77.587.111.3
    40–492,94125.799.7115.79.674.910.940.811.088.514.8
    50–591,34011.7100.6121.018.075.913.645.122.290.922.8
    ≥602522.2108.4126.425.977.116.649.333.593.630.6
BMI* (tertiles)
    <18.083,76033.0104.8111.15.770.35.340.810.583.98.4
    18.08–20.473,75733.0101.3113.86.373.07.140.810.186.610.2
    >20.473,87134.094.1119.212.778.415.740.811.792.020.9
    Unknown70
Education (years)
    No5,08944.499.0114.27.873.07.941.211.886.712.2
    <63,39229.6102.7114.17.273.59.040.59.987.112.0
    6–91,71415.0102.4115.18.875.010.540.29.688.413.9
    ≥101,25711.092.7118.312.477.615.740.710.791.120.3
    Unknown6
Tobacco smoking
    Nonsmoker7,39464.6100.6114.67.974.510.340.210.087.913.7
    Past smoker7556.6107.4118.814.375.411.443.417.189.918.7
    Current light smoker1,95917.198.5114.78.472.87.741.911.686.812.2
    Current heavy smoker1,33911.793.7113.26.871.96.441.310.685.79.9
    Unknown11
Contraceptive use (in women)
    No4,86674.3101.1113.86.573.99.939.97.787.411.9
    Yes#1,68625.796.8114.88.274.99.440.010.388.213.4
Occupation
    Daily contract laborer4206.7102.8111.75.570.13.641.69.184.07.4
    Factory worker1,14610.0100.4113.04.971.44.841.510.885.38.3
    Farmer (with own land)6886.0111.9115.39.572.87.742.514.387.011.7
    Other paid job4293.792.7119.714.177.214.442.513.091.321.0
    Small business owner/employee1,81715.992.0116.59.275.611.641.010.889.215.6
    Unemployed2362.1110.0125.325.977.619.347.729.593.532.6
    Housemaker6,16753.8100.7114.17.874.29.840.09.787.513.2
    Others5554.899.4113.16.971.86.541.210.085.69.6
TWA (μg/liter)**
    0.1–8.02,29320.52.8114.47.774.510.639.818.387.814.1
    8.1–40.82,14719.423.1115.59.273.89.241.721.687.713.6
    40.9–91.02,22520.363.8115.38.574.39.841.220.487.913.8
    91.1–176.02,21819.9128.2114.58.574.18.840.419.787.512.5
    176.1–864.02,21419.9282.8114.58.073.39.141.220.187.113.1
Overall (n = 11,458)SBP*DBP*Combination of SBP and DBP
Pulse blood pressureMeans of mean arterial pressure§General hypertension (%)
No.%Mean TWA* (μg/liter)Mean (mmHg)Systolic hypertension (SBP, ≥140 mmHg) (%)Mean (mmHg)Diastolic hypertension (DBP, ≥90 mmHg) (%)Mean (mmHg)High pulse pressure (DBP, ≥90 mmHg) (%)
Gender
    Female6,55257.2100.0114.17.874.19.839.99.687.413.1
    Male4,90642.899.8115.78.973.79.042.012.487.713.6
Age (years)
    <302,88725.299.8111.53.971.96.539.67.885.18.6
    30–394,03835.299.4113.66.273.98.739.77.587.111.3
    40–492,94125.799.7115.79.674.910.940.811.088.514.8
    50–591,34011.7100.6121.018.075.913.645.122.290.922.8
    ≥602522.2108.4126.425.977.116.649.333.593.630.6
BMI* (tertiles)
    <18.083,76033.0104.8111.15.770.35.340.810.583.98.4
    18.08–20.473,75733.0101.3113.86.373.07.140.810.186.610.2
    >20.473,87134.094.1119.212.778.415.740.811.792.020.9
    Unknown70
Education (years)
    No5,08944.499.0114.27.873.07.941.211.886.712.2
    <63,39229.6102.7114.17.273.59.040.59.987.112.0
    6–91,71415.0102.4115.18.875.010.540.29.688.413.9
    ≥101,25711.092.7118.312.477.615.740.710.791.120.3
    Unknown6
Tobacco smoking
    Nonsmoker7,39464.6100.6114.67.974.510.340.210.087.913.7
    Past smoker7556.6107.4118.814.375.411.443.417.189.918.7
    Current light smoker1,95917.198.5114.78.472.87.741.911.686.812.2
    Current heavy smoker1,33911.793.7113.26.871.96.441.310.685.79.9
    Unknown11
Contraceptive use (in women)
    No4,86674.3101.1113.86.573.99.939.97.787.411.9
    Yes#1,68625.796.8114.88.274.99.440.010.388.213.4
Occupation
    Daily contract laborer4206.7102.8111.75.570.13.641.69.184.07.4
    Factory worker1,14610.0100.4113.04.971.44.841.510.885.38.3
    Farmer (with own land)6886.0111.9115.39.572.87.742.514.387.011.7
    Other paid job4293.792.7119.714.177.214.442.513.091.321.0
    Small business owner/employee1,81715.992.0116.59.275.611.641.010.889.215.6
    Unemployed2362.1110.0125.325.977.619.347.729.593.532.6
    Housemaker6,16753.8100.7114.17.874.29.840.09.787.513.2
    Others5554.899.4113.16.971.86.541.210.085.69.6
TWA (μg/liter)**
    0.1–8.02,29320.52.8114.47.774.510.639.818.387.814.1
    8.1–40.82,14719.423.1115.59.273.89.241.721.687.713.6
    40.9–91.02,22520.363.8115.38.574.39.841.220.487.913.8
    91.1–176.02,21819.9128.2114.58.574.18.840.419.787.512.5
    176.1–864.02,21419.9282.8114.58.073.39.141.220.187.113.1
*

SBP, systolic blood pressure; DBP, diastolic blood pressure; TWA, time-weighted well arsenic concentration; BMI, body mass index.

Prevalence by category.

Pulse pressure was defined as SBP − DBP.

§

Mean arterial pressure was defined as (⅓ × (SBP + 2 × DBP)).

The median number of cigarettes per day among current smokers was used to classifiy light and heavy smokers.

#

Current use of contraceptive is defined as using any types of contraceptives, including oral contraceptive, contraceptive implant, and the injectable contraceptive.

**

Cutpoints were determined by quintiles of overall study population.

TWA was positively related to pulse pressure and SBP, and the associations were stronger in the subpopulation with the exposure level known for an average of 11.2 years. However, we did not observe any linearity of the association. In linear regression models, the increases in pulse pressure by increasing TWA quintiles were 0.00 (referent), 1.93 (95 percent confidence interval (CI): 1.18, 2.68), 1.15 (95 percent CI: 0.39, 1.90), 0.60 (95 percent CI: −0.14, 1.34), and 1.24 (95 percent CI: 0.52, 1.95) mmHg in the overall population and 0.00 (referent), 2.31 (95 percent CI: 1.44, 3.18), 1.57 (95 percent CI: 0.68, 2.46), 1.03 (95 percent CI: 0.16, 1.89), and 1.52 (95 percent CI: 0.69, 2.34) mmHg in the subpopulation. The increases in SBP by increasing TWA quintiles were 0.00 (referent), 1.81 (95 percent CI: 0.70, 2.92), 1.25 (95 percent CI: 0.13, 2.37), 0.73 (95 percent CI: −0.36, 1.81), and 1.81 (95 percent CI: −0.26, 1.87) mmHg in the overall population and 0.00 (referent), 2.03 (95 percent CI: 0.73, 3.33), 1.97 (95 percent CI: 0.64, 3.31), 0.91 (95 percent CI: −0.37, 2.19), and 1.19 (95 percent CI: −0.06, 2.43) mmHg in the subpopulation. The associations of TWA with DBP and mean arterial pressure were not apparent (data not shown).

In logistic regression models, the presence of systolic hypertension and high pulse pressure was positively related to TWA (table 2). However, the positive associations did not follow a strict dose-response relation. The higher four quintiles of arsenic exposure were associated with 19–39 percent and 24–50 percent increases in risk of high pulse pressure among the overall population and the subpopulation, respectively. There were no clear associations between TWA and either diastolic or general hypertension.

TABLE 2.

Associations of arsenic exposure with systolic hypertension, diastolic hypertension, general hypertension, and high pulse pressure, Araihazar, Bangladesh, October 2000–May 2002

TWA* (μg/liter)Mean TWA (μg/liter)Mean years with known arsenic exposureNo.Systolic hypertension (SBP,* ≥140 mmHg)Diastolic hypertension (DBP,* ≥90 mmHg)General hypertension (SBP, ≥140 and/or DBP, ≥90 mmHg)Pulse blood pressure (≥55 mmHg)
No.Odds ratio§95% confidence intervalNo.Odds ratio§95% confidence intervalNo.Odds ratio§95% confidence intervalNo.Odds ratio§95% confidence interval
Overall
    0.1–8.02.88.12,2421631.002251.002891.002051.00
    8.1–40.823.28.52,1161881.391.10, 1.751880.960.77, 1.202741.100.90, 1.332521.391.14, 1.71
    40.9–91.063.98.72,1871741.210.96, 1.542061.010.81, 1.252731.030.85, 1.252321.210.99, 1.49
    91.1–176.0128.19.22,1811781.281.01, 1.621850.930.75, 1.162591.010.83, 1.222271.190.97, 1.45
    176.1–864.0283.18.22,1841651.130.90, 1.441930.970.78, 1.202651.020.84, 1.232331.190.97, 1.46
Subpopulation with longer-term TWA#
    0.1–8.02.710.11,6151221.001641.002091.001401.00
    8.1–40.823.210.51,5511391.351.02, 1.771370.940.72, 1.221961.060.84, 1.341841.501.16, 1.91
    40.9–91.064.311.11,5431371.280.97, 1.691581.070.83, 1.382111.120.89, 1.411711.341.04, 1.73
    91.1–176.0127.211.61,6101361.300.99, 1.721350.930.72, 1.201931.030.82, 1.301761.351.05, 1.71
    176.1–864.0284.710.71,6411261.120.85, 1.471501.000.78, 1.282051.050.84, 1.311721.240.97, 1.59
TWA* (μg/liter)Mean TWA (μg/liter)Mean years with known arsenic exposureNo.Systolic hypertension (SBP,* ≥140 mmHg)Diastolic hypertension (DBP,* ≥90 mmHg)General hypertension (SBP, ≥140 and/or DBP, ≥90 mmHg)Pulse blood pressure (≥55 mmHg)
No.Odds ratio§95% confidence intervalNo.Odds ratio§95% confidence intervalNo.Odds ratio§95% confidence intervalNo.Odds ratio§95% confidence interval
Overall
    0.1–8.02.88.12,2421631.002251.002891.002051.00
    8.1–40.823.28.52,1161881.391.10, 1.751880.960.77, 1.202741.100.90, 1.332521.391.14, 1.71
    40.9–91.063.98.72,1871741.210.96, 1.542061.010.81, 1.252731.030.85, 1.252321.210.99, 1.49
    91.1–176.0128.19.22,1811781.281.01, 1.621850.930.75, 1.162591.010.83, 1.222271.190.97, 1.45
    176.1–864.0283.18.22,1841651.130.90, 1.441930.970.78, 1.202651.020.84, 1.232331.190.97, 1.46
Subpopulation with longer-term TWA#
    0.1–8.02.710.11,6151221.001641.002091.001401.00
    8.1–40.823.210.51,5511391.351.02, 1.771370.940.72, 1.221961.060.84, 1.341841.501.16, 1.91
    40.9–91.064.311.11,5431371.280.97, 1.691581.070.83, 1.382111.120.89, 1.411711.341.04, 1.73
    91.1–176.0127.211.61,6101361.300.99, 1.721350.930.72, 1.201931.030.82, 1.301761.351.05, 1.71
    176.1–864.0284.710.71,6411261.120.85, 1.471501.000.78, 1.282051.050.84, 1.311721.240.97, 1.59
*

TWA, time-weighted well arsenic concentration; SBP, systolic blood pressure; DBP, diastolic blood pressure.

Cutpoints were determined by quintiles of overall study population.

Pulse pressure was defined as SBP − DBP.

§

Odds ratios were adjusted for age, gender, body mass index, cigarette smoking status, education length, and daily water consumption.

Reference group.

#

Subpopulation with ≥5 years of known well arsenic level (n = 7,960).

TABLE 2.

Associations of arsenic exposure with systolic hypertension, diastolic hypertension, general hypertension, and high pulse pressure, Araihazar, Bangladesh, October 2000–May 2002

TWA* (μg/liter)Mean TWA (μg/liter)Mean years with known arsenic exposureNo.Systolic hypertension (SBP,* ≥140 mmHg)Diastolic hypertension (DBP,* ≥90 mmHg)General hypertension (SBP, ≥140 and/or DBP, ≥90 mmHg)Pulse blood pressure (≥55 mmHg)
No.Odds ratio§95% confidence intervalNo.Odds ratio§95% confidence intervalNo.Odds ratio§95% confidence intervalNo.Odds ratio§95% confidence interval
Overall
    0.1–8.02.88.12,2421631.002251.002891.002051.00
    8.1–40.823.28.52,1161881.391.10, 1.751880.960.77, 1.202741.100.90, 1.332521.391.14, 1.71
    40.9–91.063.98.72,1871741.210.96, 1.542061.010.81, 1.252731.030.85, 1.252321.210.99, 1.49
    91.1–176.0128.19.22,1811781.281.01, 1.621850.930.75, 1.162591.010.83, 1.222271.190.97, 1.45
    176.1–864.0283.18.22,1841651.130.90, 1.441930.970.78, 1.202651.020.84, 1.232331.190.97, 1.46
Subpopulation with longer-term TWA#
    0.1–8.02.710.11,6151221.001641.002091.001401.00
    8.1–40.823.210.51,5511391.351.02, 1.771370.940.72, 1.221961.060.84, 1.341841.501.16, 1.91
    40.9–91.064.311.11,5431371.280.97, 1.691581.070.83, 1.382111.120.89, 1.411711.341.04, 1.73
    91.1–176.0127.211.61,6101361.300.99, 1.721350.930.72, 1.201931.030.82, 1.301761.351.05, 1.71
    176.1–864.0284.710.71,6411261.120.85, 1.471501.000.78, 1.282051.050.84, 1.311721.240.97, 1.59
TWA* (μg/liter)Mean TWA (μg/liter)Mean years with known arsenic exposureNo.Systolic hypertension (SBP,* ≥140 mmHg)Diastolic hypertension (DBP,* ≥90 mmHg)General hypertension (SBP, ≥140 and/or DBP, ≥90 mmHg)Pulse blood pressure (≥55 mmHg)
No.Odds ratio§95% confidence intervalNo.Odds ratio§95% confidence intervalNo.Odds ratio§95% confidence intervalNo.Odds ratio§95% confidence interval
Overall
    0.1–8.02.88.12,2421631.002251.002891.002051.00
    8.1–40.823.28.52,1161881.391.10, 1.751880.960.77, 1.202741.100.90, 1.332521.391.14, 1.71
    40.9–91.063.98.72,1871741.210.96, 1.542061.010.81, 1.252731.030.85, 1.252321.210.99, 1.49
    91.1–176.0128.19.22,1811781.281.01, 1.621850.930.75, 1.162591.010.83, 1.222271.190.97, 1.45
    176.1–864.0283.18.22,1841651.130.90, 1.441930.970.78, 1.202651.020.84, 1.232331.190.97, 1.46
Subpopulation with longer-term TWA#
    0.1–8.02.710.11,6151221.001641.002091.001401.00
    8.1–40.823.210.51,5511391.351.02, 1.771370.940.72, 1.221961.060.84, 1.341841.501.16, 1.91
    40.9–91.064.311.11,5431371.280.97, 1.691581.070.83, 1.382111.120.89, 1.411711.341.04, 1.73
    91.1–176.0127.211.61,6101361.300.99, 1.721350.930.72, 1.201931.030.82, 1.301761.351.05, 1.71
    176.1–864.0284.710.71,6411261.120.85, 1.471501.000.78, 1.282051.050.84, 1.311721.240.97, 1.59
*

TWA, time-weighted well arsenic concentration; SBP, systolic blood pressure; DBP, diastolic blood pressure.

Cutpoints were determined by quintiles of overall study population.

Pulse pressure was defined as SBP − DBP.

§

Odds ratios were adjusted for age, gender, body mass index, cigarette smoking status, education length, and daily water consumption.

Reference group.

#

Subpopulation with ≥5 years of known well arsenic level (n = 7,960).

The positive associations of TWA with the presence of high pulse pressure and systolic hypertension were somewhat more apparent in participants with low levels of vitamins B2, B6, and B12 or folate intake compared with those with higher levels (table 3). The pattern of the odds ratios was consistent in the subpopulation. However, interaction by levels of individual nutrient intake was not statistically significant at p < 0.05. No apparent associations were observed between diastolic hypertension and TWA among participants with any given intake level of single nutrients (data not shown).

TABLE 3.

Associations of arsenic exposure with high pulse pressure and systolic hypertension by dietary intake levels of folate and vitamins B2, B6, and B12, Araihazar, Bangladesh, October 2000–May 2002

TWA* (μg/liter)Vitamin B2Vitamin B6FolateVitamin B12
Low (0.51–0.97 mg)High (0.98–3.91 mg)pinteractionLow (2.55–3.33 mg)High (3.34–8.69 mg)pinteractionLow (22.67–113.11 μg)High (113.12–753.55 μg)pinteractionLow (0.50–1.56 mg)High (1.57–9.98 mg)pinteraction
Odds ratio95% confidence intervalOdds ratio95% confidence intervalOdds ratio95% confidence intervalOdds ratio95% confidence intervalOdds ratio95% confidence intervalOdds ratio95% confidence intervalOdds ratio95% confidence intervalOdds ratio95% confidence interval
Overall study population§n = 5,389n = 5,225n = 5,366n = 5,248n = 5,388n = 5,226n = 5,373n = 5,241
High pulse pressure (pulse pressure, ≥55 mmHg)
    0.1−8.01.001.00<0.011.001.000.381.001.000.181.001.000.40
    8.1–40.81.401.03, 1.881.451.11, 1.891.471.11, 1.951.351.01, 1.811.511.13, 2.031.351.02, 1.781.651.19, 2.291.311.00, 1.72
    40.9–91.01.220.90, 1.661.190.91, 1.581.220.92, 1.611.170.87, 1.571.220.91, 1.641.190.90, 1.591.591.15, 2.210.970.73, 1.28
    91.1–176.01.561.16, 2.080.890.67, 1.181.240.94, 1.641.120.84, 1.501.371.02, 1.841.030.77, 1.361.401.02, 1.941.090.83, 1.43
    176.1–864.01.411.05, 1.911.010.77, 1.341.310.99, 1.741.060.79, 1.431.361.00, 1.841.050.79, 1.391.421.03, 1.951.090.82, 1.44
Systolic hypertension (SBP,* ≥140 mmHg)
    0.1–8.01.001.000.711.001.000.091.001.000.721.001.000.47
    8.1–40.81.340.95, 1.901.461.07, 1.991.421.02, 1.971.401.01, 1.931.370.96, 1.961.451.06, 1.971.491.02, 2.191.401.04, 1.89
    40.9–91.01.080.77, 1.511.290.93, 1.781.190.86, 1.661.180.85, 1.651.270.90, 1.791.140.82, 1.571.491.03, 2.161.020.74, 1.42
    91.1–176.01.401.00, 1.951.140.82, 1.581.471.07, 2.041.080.77, 1.511.421.01, 2.011.160.84, 1.591.491.03, 2.151.180.86, 1.61
    176.1–864.01.130.80, 1.591.160.85, 1.601.340.96, 1.860.980.69, 1.371.150.80, 1.641.160.84, 1.601.320.91, 1.901.090.79, 1.51
Subpopulation#n = 3,877n = 3,864n = 3,819n = 3,922n = 3,918n = 3,823n = 3,927n = 3,814
High pulse pressure (pulse pressure, ≥55 mmHg)
    0.1–8.01.001.00<0.011.001.000.331.001.000.201.001.000.27
    8.1–40.81.641.14, 2.371.411.01, 1.971.711.22, 2.401.320.93, 1.571.801.26, 2.551.300.92, 1.832.071.39, 3.071.230.89, 1.71
    40.9–91.01.420.99, 2.041.300.93, 1.821.451.03, 2.031.220.87, 1.731.410.99, 2.011.300.82, 1.841.881.27, 2.791.060.75, 1.49
    91.1–176.01.931.37, 2.740.890.63, 1.251.511.08, 2.121.150.82, 1.641.651.17, 2.351.070.76, 1.511.751.19, 2.591.140.83, 1.58
    176.1–864.01.591.11, 2.280.970.70, 1.351.400.99, 1.981.060.75, 1.501.471.02, 2.111.030.73, 1.451.641.11, 2.421.010.73, 1.41
Systolic hypertension (SBP, ≥140 mmHg)
    0.1–8.01.001.000.861.001.000.091.001.000.441.001.000.19
    8.1–40.81.380.93, 2.041.330.91, 1.941.360.93, 1.991.330.91, 1.951.350.90, 2.041.350.94, 1.951.470.94, 2.301.280.91, 1.85
    40.9–91.01.110.76, 1.631.230.98, 2.091.330.92, 1.931.210.82, 1.781.400.95, 2.071.170.80, 1.711.480.96, 2.261.170.81, 1.69
    91.1–176.01.471.01, 2.131.120.75, 1.651.551.07, 2.241.060.72, 1.581.541.04, 2.281.120.77, 1.621.561.03, 2.371.180.82, 1.70
    176.1–864.01.070.72, 1.591.160.80, 1.691.320.91, 1.920.940.63, 1.411.200.78, 1.791.070.74, 1.551.420.94, 2.150.930.64, 1.37
TWA* (μg/liter)Vitamin B2Vitamin B6FolateVitamin B12
Low (0.51–0.97 mg)High (0.98–3.91 mg)pinteractionLow (2.55–3.33 mg)High (3.34–8.69 mg)pinteractionLow (22.67–113.11 μg)High (113.12–753.55 μg)pinteractionLow (0.50–1.56 mg)High (1.57–9.98 mg)pinteraction
Odds ratio95% confidence intervalOdds ratio95% confidence intervalOdds ratio95% confidence intervalOdds ratio95% confidence intervalOdds ratio95% confidence intervalOdds ratio95% confidence intervalOdds ratio95% confidence intervalOdds ratio95% confidence interval
Overall study population§n = 5,389n = 5,225n = 5,366n = 5,248n = 5,388n = 5,226n = 5,373n = 5,241
High pulse pressure (pulse pressure, ≥55 mmHg)
    0.1−8.01.001.00<0.011.001.000.381.001.000.181.001.000.40
    8.1–40.81.401.03, 1.881.451.11, 1.891.471.11, 1.951.351.01, 1.811.511.13, 2.031.351.02, 1.781.651.19, 2.291.311.00, 1.72
    40.9–91.01.220.90, 1.661.190.91, 1.581.220.92, 1.611.170.87, 1.571.220.91, 1.641.190.90, 1.591.591.15, 2.210.970.73, 1.28
    91.1–176.01.561.16, 2.080.890.67, 1.181.240.94, 1.641.120.84, 1.501.371.02, 1.841.030.77, 1.361.401.02, 1.941.090.83, 1.43
    176.1–864.01.411.05, 1.911.010.77, 1.341.310.99, 1.741.060.79, 1.431.361.00, 1.841.050.79, 1.391.421.03, 1.951.090.82, 1.44
Systolic hypertension (SBP,* ≥140 mmHg)
    0.1–8.01.001.000.711.001.000.091.001.000.721.001.000.47
    8.1–40.81.340.95, 1.901.461.07, 1.991.421.02, 1.971.401.01, 1.931.370.96, 1.961.451.06, 1.971.491.02, 2.191.401.04, 1.89
    40.9–91.01.080.77, 1.511.290.93, 1.781.190.86, 1.661.180.85, 1.651.270.90, 1.791.140.82, 1.571.491.03, 2.161.020.74, 1.42
    91.1–176.01.401.00, 1.951.140.82, 1.581.471.07, 2.041.080.77, 1.511.421.01, 2.011.160.84, 1.591.491.03, 2.151.180.86, 1.61
    176.1–864.01.130.80, 1.591.160.85, 1.601.340.96, 1.860.980.69, 1.371.150.80, 1.641.160.84, 1.601.320.91, 1.901.090.79, 1.51
Subpopulation#n = 3,877n = 3,864n = 3,819n = 3,922n = 3,918n = 3,823n = 3,927n = 3,814
High pulse pressure (pulse pressure, ≥55 mmHg)
    0.1–8.01.001.00<0.011.001.000.331.001.000.201.001.000.27
    8.1–40.81.641.14, 2.371.411.01, 1.971.711.22, 2.401.320.93, 1.571.801.26, 2.551.300.92, 1.832.071.39, 3.071.230.89, 1.71
    40.9–91.01.420.99, 2.041.300.93, 1.821.451.03, 2.031.220.87, 1.731.410.99, 2.011.300.82, 1.841.881.27, 2.791.060.75, 1.49
    91.1–176.01.931.37, 2.740.890.63, 1.251.511.08, 2.121.150.82, 1.641.651.17, 2.351.070.76, 1.511.751.19, 2.591.140.83, 1.58
    176.1–864.01.591.11, 2.280.970.70, 1.351.400.99, 1.981.060.75, 1.501.471.02, 2.111.030.73, 1.451.641.11, 2.421.010.73, 1.41
Systolic hypertension (SBP, ≥140 mmHg)
    0.1–8.01.001.000.861.001.000.091.001.000.441.001.000.19
    8.1–40.81.380.93, 2.041.330.91, 1.941.360.93, 1.991.330.91, 1.951.350.90, 2.041.350.94, 1.951.470.94, 2.301.280.91, 1.85
    40.9–91.01.110.76, 1.631.230.98, 2.091.330.92, 1.931.210.82, 1.781.400.95, 2.071.170.80, 1.711.480.96, 2.261.170.81, 1.69
    91.1–176.01.471.01, 2.131.120.75, 1.651.551.07, 2.241.060.72, 1.581.541.04, 2.281.120.77, 1.621.561.03, 2.371.180.82, 1.70
    176.1–864.01.070.72, 1.591.160.80, 1.691.320.91, 1.920.940.63, 1.411.200.78, 1.791.070.74, 1.551.420.94, 2.150.930.64, 1.37
*

TWA, time-weighted well arsenic concentration; SBP, systolic blood pressure.

Cutpoints were determined by median values in the overall study population.

Odds ratios were adjusted for age, gender, body mass index, cigarette smoking status, education length, daily water consumption, and total energy intake.

§

Subjects with unknown nutrient intake (n = 296) in the overall study population were excluded from the analysis.

Reference group.

#

Subpopulation with ≥5 years of known well arsenic level (n = 7,741); subjects with unknown nutrient intake (n = 291) in the subpopulation were excluded from the analysis.

TABLE 3.

Associations of arsenic exposure with high pulse pressure and systolic hypertension by dietary intake levels of folate and vitamins B2, B6, and B12, Araihazar, Bangladesh, October 2000–May 2002

TWA* (μg/liter)Vitamin B2Vitamin B6FolateVitamin B12
Low (0.51–0.97 mg)High (0.98–3.91 mg)pinteractionLow (2.55–3.33 mg)High (3.34–8.69 mg)pinteractionLow (22.67–113.11 μg)High (113.12–753.55 μg)pinteractionLow (0.50–1.56 mg)High (1.57–9.98 mg)pinteraction
Odds ratio95% confidence intervalOdds ratio95% confidence intervalOdds ratio95% confidence intervalOdds ratio95% confidence intervalOdds ratio95% confidence intervalOdds ratio95% confidence intervalOdds ratio95% confidence intervalOdds ratio95% confidence interval
Overall study population§n = 5,389n = 5,225n = 5,366n = 5,248n = 5,388n = 5,226n = 5,373n = 5,241
High pulse pressure (pulse pressure, ≥55 mmHg)
    0.1−8.01.001.00<0.011.001.000.381.001.000.181.001.000.40
    8.1–40.81.401.03, 1.881.451.11, 1.891.471.11, 1.951.351.01, 1.811.511.13, 2.031.351.02, 1.781.651.19, 2.291.311.00, 1.72
    40.9–91.01.220.90, 1.661.190.91, 1.581.220.92, 1.611.170.87, 1.571.220.91, 1.641.190.90, 1.591.591.15, 2.210.970.73, 1.28
    91.1–176.01.561.16, 2.080.890.67, 1.181.240.94, 1.641.120.84, 1.501.371.02, 1.841.030.77, 1.361.401.02, 1.941.090.83, 1.43
    176.1–864.01.411.05, 1.911.010.77, 1.341.310.99, 1.741.060.79, 1.431.361.00, 1.841.050.79, 1.391.421.03, 1.951.090.82, 1.44
Systolic hypertension (SBP,* ≥140 mmHg)
    0.1–8.01.001.000.711.001.000.091.001.000.721.001.000.47
    8.1–40.81.340.95, 1.901.461.07, 1.991.421.02, 1.971.401.01, 1.931.370.96, 1.961.451.06, 1.971.491.02, 2.191.401.04, 1.89
    40.9–91.01.080.77, 1.511.290.93, 1.781.190.86, 1.661.180.85, 1.651.270.90, 1.791.140.82, 1.571.491.03, 2.161.020.74, 1.42
    91.1–176.01.401.00, 1.951.140.82, 1.581.471.07, 2.041.080.77, 1.511.421.01, 2.011.160.84, 1.591.491.03, 2.151.180.86, 1.61
    176.1–864.01.130.80, 1.591.160.85, 1.601.340.96, 1.860.980.69, 1.371.150.80, 1.641.160.84, 1.601.320.91, 1.901.090.79, 1.51
Subpopulation#n = 3,877n = 3,864n = 3,819n = 3,922n = 3,918n = 3,823n = 3,927n = 3,814
High pulse pressure (pulse pressure, ≥55 mmHg)
    0.1–8.01.001.00<0.011.001.000.331.001.000.201.001.000.27
    8.1–40.81.641.14, 2.371.411.01, 1.971.711.22, 2.401.320.93, 1.571.801.26, 2.551.300.92, 1.832.071.39, 3.071.230.89, 1.71
    40.9–91.01.420.99, 2.041.300.93, 1.821.451.03, 2.031.220.87, 1.731.410.99, 2.011.300.82, 1.841.881.27, 2.791.060.75, 1.49
    91.1–176.01.931.37, 2.740.890.63, 1.251.511.08, 2.121.150.82, 1.641.651.17, 2.351.070.76, 1.511.751.19, 2.591.140.83, 1.58
    176.1–864.01.591.11, 2.280.970.70, 1.351.400.99, 1.981.060.75, 1.501.471.02, 2.111.030.73, 1.451.641.11, 2.421.010.73, 1.41
Systolic hypertension (SBP, ≥140 mmHg)
    0.1–8.01.001.000.861.001.000.091.001.000.441.001.000.19
    8.1–40.81.380.93, 2.041.330.91, 1.941.360.93, 1.991.330.91, 1.951.350.90, 2.041.350.94, 1.951.470.94, 2.301.280.91, 1.85
    40.9–91.01.110.76, 1.631.230.98, 2.091.330.92, 1.931.210.82, 1.781.400.95, 2.071.170.80, 1.711.480.96, 2.261.170.81, 1.69
    91.1–176.01.471.01, 2.131.120.75, 1.651.551.07, 2.241.060.72, 1.581.541.04, 2.281.120.77, 1.621.561.03, 2.371.180.82, 1.70
    176.1–864.01.070.72, 1.591.160.80, 1.691.320.91, 1.920.940.63, 1.411.200.78, 1.791.070.74, 1.551.420.94, 2.150.930.64, 1.37
TWA* (μg/liter)Vitamin B2Vitamin B6FolateVitamin B12
Low (0.51–0.97 mg)High (0.98–3.91 mg)pinteractionLow (2.55–3.33 mg)High (3.34–8.69 mg)pinteractionLow (22.67–113.11 μg)High (113.12–753.55 μg)pinteractionLow (0.50–1.56 mg)High (1.57–9.98 mg)pinteraction
Odds ratio95% confidence intervalOdds ratio95% confidence intervalOdds ratio95% confidence intervalOdds ratio95% confidence intervalOdds ratio95% confidence intervalOdds ratio95% confidence intervalOdds ratio95% confidence intervalOdds ratio95% confidence interval
Overall study population§n = 5,389n = 5,225n = 5,366n = 5,248n = 5,388n = 5,226n = 5,373n = 5,241
High pulse pressure (pulse pressure, ≥55 mmHg)
    0.1−8.01.001.00<0.011.001.000.381.001.000.181.001.000.40
    8.1–40.81.401.03, 1.881.451.11, 1.891.471.11, 1.951.351.01, 1.811.511.13, 2.031.351.02, 1.781.651.19, 2.291.311.00, 1.72
    40.9–91.01.220.90, 1.661.190.91, 1.581.220.92, 1.611.170.87, 1.571.220.91, 1.641.190.90, 1.591.591.15, 2.210.970.73, 1.28
    91.1–176.01.561.16, 2.080.890.67, 1.181.240.94, 1.641.120.84, 1.501.371.02, 1.841.030.77, 1.361.401.02, 1.941.090.83, 1.43
    176.1–864.01.411.05, 1.911.010.77, 1.341.310.99, 1.741.060.79, 1.431.361.00, 1.841.050.79, 1.391.421.03, 1.951.090.82, 1.44
Systolic hypertension (SBP,* ≥140 mmHg)
    0.1–8.01.001.000.711.001.000.091.001.000.721.001.000.47
    8.1–40.81.340.95, 1.901.461.07, 1.991.421.02, 1.971.401.01, 1.931.370.96, 1.961.451.06, 1.971.491.02, 2.191.401.04, 1.89
    40.9–91.01.080.77, 1.511.290.93, 1.781.190.86, 1.661.180.85, 1.651.270.90, 1.791.140.82, 1.571.491.03, 2.161.020.74, 1.42
    91.1–176.01.401.00, 1.951.140.82, 1.581.471.07, 2.041.080.77, 1.511.421.01, 2.011.160.84, 1.591.491.03, 2.151.180.86, 1.61
    176.1–864.01.130.80, 1.591.160.85, 1.601.340.96, 1.860.980.69, 1.371.150.80, 1.641.160.84, 1.601.320.91, 1.901.090.79, 1.51
Subpopulation#n = 3,877n = 3,864n = 3,819n = 3,922n = 3,918n = 3,823n = 3,927n = 3,814
High pulse pressure (pulse pressure, ≥55 mmHg)
    0.1–8.01.001.00<0.011.001.000.331.001.000.201.001.000.27
    8.1–40.81.641.14, 2.371.411.01, 1.971.711.22, 2.401.320.93, 1.571.801.26, 2.551.300.92, 1.832.071.39, 3.071.230.89, 1.71
    40.9–91.01.420.99, 2.041.300.93, 1.821.451.03, 2.031.220.87, 1.731.410.99, 2.011.300.82, 1.841.881.27, 2.791.060.75, 1.49
    91.1–176.01.931.37, 2.740.890.63, 1.251.511.08, 2.121.150.82, 1.641.651.17, 2.351.070.76, 1.511.751.19, 2.591.140.83, 1.58
    176.1–864.01.591.11, 2.280.970.70, 1.351.400.99, 1.981.060.75, 1.501.471.02, 2.111.030.73, 1.451.641.11, 2.421.010.73, 1.41
Systolic hypertension (SBP, ≥140 mmHg)
    0.1–8.01.001.000.861.001.000.091.001.000.441.001.000.19
    8.1–40.81.380.93, 2.041.330.91, 1.941.360.93, 1.991.330.91, 1.951.350.90, 2.041.350.94, 1.951.470.94, 2.301.280.91, 1.85
    40.9–91.01.110.76, 1.631.230.98, 2.091.330.92, 1.931.210.82, 1.781.400.95, 2.071.170.80, 1.711.480.96, 2.261.170.81, 1.69
    91.1–176.01.471.01, 2.131.120.75, 1.651.551.07, 2.241.060.72, 1.581.541.04, 2.281.120.77, 1.621.561.03, 2.371.180.82, 1.70
    176.1–864.01.070.72, 1.591.160.80, 1.691.320.91, 1.920.940.63, 1.411.200.78, 1.791.070.74, 1.551.420.94, 2.150.930.64, 1.37
*

TWA, time-weighted well arsenic concentration; SBP, systolic blood pressure.

Cutpoints were determined by median values in the overall study population.

Odds ratios were adjusted for age, gender, body mass index, cigarette smoking status, education length, daily water consumption, and total energy intake.

§

Subjects with unknown nutrient intake (n = 296) in the overall study population were excluded from the analysis.

Reference group.

#

Subpopulation with ≥5 years of known well arsenic level (n = 7,741); subjects with unknown nutrient intake (n = 291) in the subpopulation were excluded from the analysis.

Average daily energy-adjusted intakes of vitamins B2, B6, and B12 and folate by the composite measure of the four nutrients are presented in table 4. The higher the score on the composite measure, the higher the intake values were for each of the nutrients.

TABLE 4.

Average daily intakes of folate and vitamins B6, B2, and B12 by the composite measure of the four nutrients, Araihazar, Bangladesh, October 2000–May 2002

Low intake level, score* 0 (n = 2,143)Medium intake levelHigh intake level
Score 1 (n = 2,238)Score 2 (n = 1,910)Score 3 (n = 2,410)Score 4 (n = 1,913)
Folate (μg)84.24 (15.81)94.76 (19.21)113.82 (26.76)149.24 (47.21)180.27 (70.93)
Vitamin B6 (mg)3.16 (0.11)3.30 (0.21)3.39 (0.29)3.46 (0.35)3.79 (4.11)
Vitamin B2 (mg)0.82 (0.07)0.87 (0.08)0.98 (0.11)1.13 (0.17)1.29 (0.69)
Vitamin B12 (mg)0.88 (0.39)1.50 (0.93)1.77 (1.10)2.07 (1.27)2.88 (1.30)
Low intake level, score* 0 (n = 2,143)Medium intake levelHigh intake level
Score 1 (n = 2,238)Score 2 (n = 1,910)Score 3 (n = 2,410)Score 4 (n = 1,913)
Folate (μg)84.24 (15.81)94.76 (19.21)113.82 (26.76)149.24 (47.21)180.27 (70.93)
Vitamin B6 (mg)3.16 (0.11)3.30 (0.21)3.39 (0.29)3.46 (0.35)3.79 (4.11)
Vitamin B2 (mg)0.82 (0.07)0.87 (0.08)0.98 (0.11)1.13 (0.17)1.29 (0.69)
Vitamin B12 (mg)0.88 (0.39)1.50 (0.93)1.77 (1.10)2.07 (1.27)2.88 (1.30)
*

Score on the composite measure.

Numbers in parentheses, standard error.

TABLE 4.

Average daily intakes of folate and vitamins B6, B2, and B12 by the composite measure of the four nutrients, Araihazar, Bangladesh, October 2000–May 2002

Low intake level, score* 0 (n = 2,143)Medium intake levelHigh intake level
Score 1 (n = 2,238)Score 2 (n = 1,910)Score 3 (n = 2,410)Score 4 (n = 1,913)
Folate (μg)84.24 (15.81)94.76 (19.21)113.82 (26.76)149.24 (47.21)180.27 (70.93)
Vitamin B6 (mg)3.16 (0.11)3.30 (0.21)3.39 (0.29)3.46 (0.35)3.79 (4.11)
Vitamin B2 (mg)0.82 (0.07)0.87 (0.08)0.98 (0.11)1.13 (0.17)1.29 (0.69)
Vitamin B12 (mg)0.88 (0.39)1.50 (0.93)1.77 (1.10)2.07 (1.27)2.88 (1.30)
Low intake level, score* 0 (n = 2,143)Medium intake levelHigh intake level
Score 1 (n = 2,238)Score 2 (n = 1,910)Score 3 (n = 2,410)Score 4 (n = 1,913)
Folate (μg)84.24 (15.81)94.76 (19.21)113.82 (26.76)149.24 (47.21)180.27 (70.93)
Vitamin B6 (mg)3.16 (0.11)3.30 (0.21)3.39 (0.29)3.46 (0.35)3.79 (4.11)
Vitamin B2 (mg)0.82 (0.07)0.87 (0.08)0.98 (0.11)1.13 (0.17)1.29 (0.69)
Vitamin B12 (mg)0.88 (0.39)1.50 (0.93)1.77 (1.10)2.07 (1.27)2.88 (1.30)
*

Score on the composite measure.

Numbers in parentheses, standard error.

Among participants with all four nutrient intakes lower than the average level (0 score on the composite variable), the odds ratios for high pulse pressure comparing higher quintiles with the bottom quintile of TWA ranged from 1.83 to 1.89, with all of the 95 percent confidence intervals excluding unity (table 5). The associations of higher levels of TWA with systolic hypertension also appear to be stronger, albeit weaker compared with those with high pulse pressure, in participants with lower intake levels of folate and the B vitamins. These results are consistent in the subpopulation. Odds ratios for general hypertension in participants with lower than average intake of B vitamins and folate were greater than those in participants with higher intake levels. However, the associations were not significant; the odds ratios for general hypertension by increasing TWA quintiles were 1.00 (referent), 1.05 (95 percent CI: 0.66, 1.68), 1.24 (95 percent CI: 0.80, 1.94), 1.38 (95 percent CI: 0.88, 2.14), and 1.28 (95 percent CI: 0.76, 1.83), respectively, with lower intake levels of folate and the B vitamins.

TABLE 5.

Associations of arsenic exposure with high pulse pressure and systolic hypertension by combined dietary intake levels of folate and vitamins B2, B6, and B12, Araihazar, Bangladesh, October 2000–May 2002

TWA* (μg/liter)Low intake levelMedium intake levelHigh intake levelpinteraction (low vs. medium level)pinteraction (low vs. high level)
No. of casesNo. of noncasesMean TWA (μg/liter)Odds ratio§95% confidence intervalNo. of casesNo. of noncasesMean TWA (μg/liter)Odds ratio§95% confidence intervalNo. of casesNo. of noncasesMean TWA (μg/liter)Odds ratio§95% confidence interval
Overall study population
High pulse pressure (pulse pressure, ≥55 mmHg)
    0.1–8.0#223413.11.00727542.71.001068862.81.000.260.03
    8.1–40.84436623.71.841.07, 3.1610270323.41.631.17, 2.2510474622.71.200.89, 1.61
    40.9–91.04839863.11.891.11, 3.208678263.61.170.84, 1.639072164.61.080.79, 1.45
    91.1–176.050401128.91.831.09, 3.0798741127.61.431.04, 1.9874759128.50.850.62, 1.17
    176.1–864.053420282.51.891.12, 3.2086724283.51.260.90, 1.7688749281.40.980.72, 1.32
Systolic hypertension (SBP,* ≥140 mmHg)
    0.1–8.0#183453.11.00505482.71.00736392.81.000.390.34
    8.1–40.82938123.71.410.76, 2.637552623.41.651.13, 2.437357722.71.260.90, 1.77
    40.9–91.03241463.11.540.84, 2.816655463.61.070.72, 1.576651164.61.220.86, 1.73
    91.1–176.043408128.91.961.10, 3.4983573127.61.300.88, 1.9449540128.51.040.73, 1.49
    176.1–864.031442282.51.310.71, 2.4158538283.51.190.80, 1.7868585281.41.100.78, 1.55
Subpopulation**
High pulse pressure (pulse pressure, ≥55 mmHg)
    0.1–8.0#132431.91.00577691.61.00839091.71.000.210.01
    8.1–40.83523525.02.771.40, 5.487473124.01.761.20, 2.578276822.01.120.78, 1.61
    40.9–91.03526961.12.461.25, 1.826080862.01.370.93, 2.017473766.01.120.77, 1.61
    91.1–176.040280124.02.601.34, 5.0266773123.01.701.17, 2.4863770124.00.810.55, 1.18
    176.1–864.040299266.02.531.30, 4.9159751260.01.230.82, 1.8372765248.10.960.67, 1.37
Systolic hypertension (SBP, ≥140 mmHg)
    0.1–8.0#162401.91.00445541.61.00586541.71.000.470.35
    8.1–40.82424625.01.450.73, 2.885155024.01.480.95, 2.326158922.01.230.82, 1.83
    40.9–91.02527961.11.420.72, 2.795057062.01.210.78, 1.865752066.01.300.86, 1.95
    91.1–176.032288124.01.760.93, 3.3359597123.01.500.97, 2.3542547124.00.950.62, 1.48
    176.1–864.026313266.01.380.71, 2.6739557260.01.030.65, 1.6458595248.11.100.73, 1.65
TWA* (μg/liter)Low intake levelMedium intake levelHigh intake levelpinteraction (low vs. medium level)pinteraction (low vs. high level)
No. of casesNo. of noncasesMean TWA (μg/liter)Odds ratio§95% confidence intervalNo. of casesNo. of noncasesMean TWA (μg/liter)Odds ratio§95% confidence intervalNo. of casesNo. of noncasesMean TWA (μg/liter)Odds ratio§95% confidence interval
Overall study population
High pulse pressure (pulse pressure, ≥55 mmHg)
    0.1–8.0#223413.11.00727542.71.001068862.81.000.260.03
    8.1–40.84436623.71.841.07, 3.1610270323.41.631.17, 2.2510474622.71.200.89, 1.61
    40.9–91.04839863.11.891.11, 3.208678263.61.170.84, 1.639072164.61.080.79, 1.45
    91.1–176.050401128.91.831.09, 3.0798741127.61.431.04, 1.9874759128.50.850.62, 1.17
    176.1–864.053420282.51.891.12, 3.2086724283.51.260.90, 1.7688749281.40.980.72, 1.32
Systolic hypertension (SBP,* ≥140 mmHg)
    0.1–8.0#183453.11.00505482.71.00736392.81.000.390.34
    8.1–40.82938123.71.410.76, 2.637552623.41.651.13, 2.437357722.71.260.90, 1.77
    40.9–91.03241463.11.540.84, 2.816655463.61.070.72, 1.576651164.61.220.86, 1.73
    91.1–176.043408128.91.961.10, 3.4983573127.61.300.88, 1.9449540128.51.040.73, 1.49
    176.1–864.031442282.51.310.71, 2.4158538283.51.190.80, 1.7868585281.41.100.78, 1.55
Subpopulation**
High pulse pressure (pulse pressure, ≥55 mmHg)
    0.1–8.0#132431.91.00577691.61.00839091.71.000.210.01
    8.1–40.83523525.02.771.40, 5.487473124.01.761.20, 2.578276822.01.120.78, 1.61
    40.9–91.03526961.12.461.25, 1.826080862.01.370.93, 2.017473766.01.120.77, 1.61
    91.1–176.040280124.02.601.34, 5.0266773123.01.701.17, 2.4863770124.00.810.55, 1.18
    176.1–864.040299266.02.531.30, 4.9159751260.01.230.82, 1.8372765248.10.960.67, 1.37
Systolic hypertension (SBP, ≥140 mmHg)
    0.1–8.0#162401.91.00445541.61.00586541.71.000.470.35
    8.1–40.82424625.01.450.73, 2.885155024.01.480.95, 2.326158922.01.230.82, 1.83
    40.9–91.02527961.11.420.72, 2.795057062.01.210.78, 1.865752066.01.300.86, 1.95
    91.1–176.032288124.01.760.93, 3.3359597123.01.500.97, 2.3542547124.00.950.62, 1.48
    176.1–864.026313266.01.380.71, 2.6739557260.01.030.65, 1.6458595248.11.100.73, 1.65
*

TWA, time-weighted well arsenic concentration; SBP, systolic blood pressure.

Cutpoints were determined by quintile values in the overall study population.

Low intake level (overall study population: n = 2,143; subpopulation: n = 1,489); medium intake level (overall study population: n = 4,148; subpopulation: n = 3,071); high intake level (overall study population: n = 4,323; subpopulation: n = 3,181).

§

Odds ratios were adjusted for age, gender, body mass index, cigarette smoking status, education length, daily water consumption, and total energy intake.

Subjects with unknown nutrient intake (n = 296) in the overall study population were excluded from the analysis.

#

Reference group.

**

Subpopulation with ≥5 years of known well arsenic level (n = 7,741); subjects with unknown nutrient intake (n = 291) in the subpopulation were excluded from the analysis.

TABLE 5.

Associations of arsenic exposure with high pulse pressure and systolic hypertension by combined dietary intake levels of folate and vitamins B2, B6, and B12, Araihazar, Bangladesh, October 2000–May 2002

TWA* (μg/liter)Low intake levelMedium intake levelHigh intake levelpinteraction (low vs. medium level)pinteraction (low vs. high level)
No. of casesNo. of noncasesMean TWA (μg/liter)Odds ratio§95% confidence intervalNo. of casesNo. of noncasesMean TWA (μg/liter)Odds ratio§95% confidence intervalNo. of casesNo. of noncasesMean TWA (μg/liter)Odds ratio§95% confidence interval
Overall study population
High pulse pressure (pulse pressure, ≥55 mmHg)
    0.1–8.0#223413.11.00727542.71.001068862.81.000.260.03
    8.1–40.84436623.71.841.07, 3.1610270323.41.631.17, 2.2510474622.71.200.89, 1.61
    40.9–91.04839863.11.891.11, 3.208678263.61.170.84, 1.639072164.61.080.79, 1.45
    91.1–176.050401128.91.831.09, 3.0798741127.61.431.04, 1.9874759128.50.850.62, 1.17
    176.1–864.053420282.51.891.12, 3.2086724283.51.260.90, 1.7688749281.40.980.72, 1.32
Systolic hypertension (SBP,* ≥140 mmHg)
    0.1–8.0#183453.11.00505482.71.00736392.81.000.390.34
    8.1–40.82938123.71.410.76, 2.637552623.41.651.13, 2.437357722.71.260.90, 1.77
    40.9–91.03241463.11.540.84, 2.816655463.61.070.72, 1.576651164.61.220.86, 1.73
    91.1–176.043408128.91.961.10, 3.4983573127.61.300.88, 1.9449540128.51.040.73, 1.49
    176.1–864.031442282.51.310.71, 2.4158538283.51.190.80, 1.7868585281.41.100.78, 1.55
Subpopulation**
High pulse pressure (pulse pressure, ≥55 mmHg)
    0.1–8.0#132431.91.00577691.61.00839091.71.000.210.01
    8.1–40.83523525.02.771.40, 5.487473124.01.761.20, 2.578276822.01.120.78, 1.61
    40.9–91.03526961.12.461.25, 1.826080862.01.370.93, 2.017473766.01.120.77, 1.61
    91.1–176.040280124.02.601.34, 5.0266773123.01.701.17, 2.4863770124.00.810.55, 1.18
    176.1–864.040299266.02.531.30, 4.9159751260.01.230.82, 1.8372765248.10.960.67, 1.37
Systolic hypertension (SBP, ≥140 mmHg)
    0.1–8.0#162401.91.00445541.61.00586541.71.000.470.35
    8.1–40.82424625.01.450.73, 2.885155024.01.480.95, 2.326158922.01.230.82, 1.83
    40.9–91.02527961.11.420.72, 2.795057062.01.210.78, 1.865752066.01.300.86, 1.95
    91.1–176.032288124.01.760.93, 3.3359597123.01.500.97, 2.3542547124.00.950.62, 1.48
    176.1–864.026313266.01.380.71, 2.6739557260.01.030.65, 1.6458595248.11.100.73, 1.65
TWA* (μg/liter)Low intake levelMedium intake levelHigh intake levelpinteraction (low vs. medium level)pinteraction (low vs. high level)
No. of casesNo. of noncasesMean TWA (μg/liter)Odds ratio§95% confidence intervalNo. of casesNo. of noncasesMean TWA (μg/liter)Odds ratio§95% confidence intervalNo. of casesNo. of noncasesMean TWA (μg/liter)Odds ratio§95% confidence interval
Overall study population
High pulse pressure (pulse pressure, ≥55 mmHg)
    0.1–8.0#223413.11.00727542.71.001068862.81.000.260.03
    8.1–40.84436623.71.841.07, 3.1610270323.41.631.17, 2.2510474622.71.200.89, 1.61
    40.9–91.04839863.11.891.11, 3.208678263.61.170.84, 1.639072164.61.080.79, 1.45
    91.1–176.050401128.91.831.09, 3.0798741127.61.431.04, 1.9874759128.50.850.62, 1.17
    176.1–864.053420282.51.891.12, 3.2086724283.51.260.90, 1.7688749281.40.980.72, 1.32
Systolic hypertension (SBP,* ≥140 mmHg)
    0.1–8.0#183453.11.00505482.71.00736392.81.000.390.34
    8.1–40.82938123.71.410.76, 2.637552623.41.651.13, 2.437357722.71.260.90, 1.77
    40.9–91.03241463.11.540.84, 2.816655463.61.070.72, 1.576651164.61.220.86, 1.73
    91.1–176.043408128.91.961.10, 3.4983573127.61.300.88, 1.9449540128.51.040.73, 1.49
    176.1–864.031442282.51.310.71, 2.4158538283.51.190.80, 1.7868585281.41.100.78, 1.55
Subpopulation**
High pulse pressure (pulse pressure, ≥55 mmHg)
    0.1–8.0#132431.91.00577691.61.00839091.71.000.210.01
    8.1–40.83523525.02.771.40, 5.487473124.01.761.20, 2.578276822.01.120.78, 1.61
    40.9–91.03526961.12.461.25, 1.826080862.01.370.93, 2.017473766.01.120.77, 1.61
    91.1–176.040280124.02.601.34, 5.0266773123.01.701.17, 2.4863770124.00.810.55, 1.18
    176.1–864.040299266.02.531.30, 4.9159751260.01.230.82, 1.8372765248.10.960.67, 1.37
Systolic hypertension (SBP, ≥140 mmHg)
    0.1–8.0#162401.91.00445541.61.00586541.71.000.470.35
    8.1–40.82424625.01.450.73, 2.885155024.01.480.95, 2.326158922.01.230.82, 1.83
    40.9–91.02527961.11.420.72, 2.795057062.01.210.78, 1.865752066.01.300.86, 1.95
    91.1–176.032288124.01.760.93, 3.3359597123.01.500.97, 2.3542547124.00.950.62, 1.48
    176.1–864.026313266.01.380.71, 2.6739557260.01.030.65, 1.6458595248.11.100.73, 1.65
*

TWA, time-weighted well arsenic concentration; SBP, systolic blood pressure.

Cutpoints were determined by quintile values in the overall study population.

Low intake level (overall study population: n = 2,143; subpopulation: n = 1,489); medium intake level (overall study population: n = 4,148; subpopulation: n = 3,071); high intake level (overall study population: n = 4,323; subpopulation: n = 3,181).

§

Odds ratios were adjusted for age, gender, body mass index, cigarette smoking status, education length, daily water consumption, and total energy intake.

Subjects with unknown nutrient intake (n = 296) in the overall study population were excluded from the analysis.

#

Reference group.

**

Subpopulation with ≥5 years of known well arsenic level (n = 7,741); subjects with unknown nutrient intake (n = 291) in the subpopulation were excluded from the analysis.

DISCUSSION

We found that arsenic exposure was positively associated with systolic hypertension and high pulse pressure, and the associations were more pronounced among participants with lower intake levels of folate and the B vitamins. No apparent association was observed between arsenic exposure and general hypertension.

High systolic blood pressure and a widening pulse pressure have been indicated as a consequence of arteriosclerosis and arterial stiffness (39, 40). It has been found that persons with a high pulse pressure had greater left ventricular mass and greater carotid intimal-medial thickness compared with those with lower pulse pressure, despite a similar mean diastolic blood pressure (41, 42). A high pulse pressure and a high systolic blood pressure have been indicated as independent predictors of cardiovascular disease-related mortality (43–45).

The exact mechanisms by which arsenic induces high systolic blood pressure and pulse pressure are not clear. Arsenic may promote inflammatory activity. Low concentrations of arsenite (As3+) have been associated with increased superoxide accumulation in porcine aortic endothelial cells (46, 47). In addition, arsenic may impair formation of endothelial nitric oxide (48, 49). Levels of endothelial nitric oxide play an important role in maintaining vascular tone (50).

Three other cross-sectional studies have investigated the association between arsenic exposure and general hypertension. Chen et al. (3) found a dose-response relation between arsenic exposure and hypertension in southwestern Taiwan, where the median well arsenic concentration in villages ranged from 700 to 930 μg/liter (51). Rahman et al. (4) observed a positive association of hypertension with arsenic exposure in Bangladesh; the range of exposure categories was, however, very wide (0, <500, 500–1,000, >1,000 μg/liter). Recently, a cross-sectional study in Wisconsin found that respondents with well-water arsenic concentrations greater than 10 μg/liter were more likely to report having had high blood pressure than were respondents whose well water had arsenic concentrations less than 2 μg/liter (52). However, analysis was based on self-reported health data.

A systematic review of the literature on the association between arsenic exposure and cardiovascular disease concluded that the evidence from southwestern Taiwan is consistent with a role of high arsenic exposure in atherosclerosis and that the cardiovascular effects of chronic low-level arsenic exposure are unknown (9). Importantly, several studies have assessed the associations between risks of cardiovascular diseases and low-level arsenic exposure. An ecologic study found elevated standardized motorality ratios for diseases of the arteries, arterioles, and capillaries in US counties with a water arsenic concentration greater than 20 μg/liter (53). The mortality of hypertensive heart disease was elevated in members of the Mormons in Millard County, Utah, with <200 μg/liter of arsenic in drinking water compared with that of the general population in Utah (54). No dose-response relation was observed in the two above-mentioned studies.

A dose-response relation may be absent in the range of arsenic exposure in the study population (0–864 μg/liter; mean and median were 101 and 62 μg/liter, respectively). We note that mechanistic studies have demonstrated that the vascular effect of arsenic is nonlinear (55). Alternatively, nondifferential measurement errors in blood pressure and arsenic exposure may have obscured a possible underlying dose-response association. Casual blood pressure readings are not an optimal representation of the entire 24-hour blood pressure pattern. However, we did not detect any systematic measurement errors in blood pressure measurements, and the reliability of blood pressure measurements between consecutive measurements was good. In addition, the relations of blood pressure and conventional risk factors were consistent with those of the literature, further suggesting the validity of the blood pressure measurement in this study.

Many studies used ecologic measures of arsenic exposure or unreliable outcome measures (7, 51–54). On the other hand, arsenic exposure was assessed individually, and blood pressure was measured with a standardized protocol in the present study with a large sample size. The study was population based, and therefore the selection of participants was not dependent on either arsenic exposure or blood pressure status. The validity of self-reported well-use history was good, since the correlation between the arsenic concentration in the current well and urinary arsenic was 0.70 (24). Additional statistical adjustments for factors related to blood pressure, such as contraceptive use in women and occupation, did not change the odds ratios appreciably. However, the possibility of uncontrolled confounding cannot be entirely excluded. We were not able to ascertain a complete lifetime history of well use with which to construct the exposure index. However, the odds ratios for systolic hypertension and high pulse pressure in relation to arsenic exposure were similar, if not greater, in the subpopulation with 11.2 years of known well arsenic on average, suggesting a long-term effect of arsenic exposure.

We found stronger associations of arsenic exposure with systolic hypertension and high pulse pressure among participants with a low intake level of folate and the B vitamins (table 5). The literature has suggested a role of these nutrients and homocysteine in the etiology of vascular diseases (56–58). Methylation of arsenic, a hypothesized detoxification pathway, requires the conversion of S-adenosylmethionine to S-adenosylhomocysteine, which results in homocysteine (19, 20). Homocysteine can be remethylated to methionine by a folate-dependent reaction that is catalyzed by methionine synthase, a vitamin B12-dependent enzyme. Alternately, homocysteine may be metabolized to cysteine in reactions catalyzed by two vitamin B6-dependent enzymes (23). Our finding is consistent with the hypothesis that individuals with insufficient intakes of nutrients related to both endothelial function and arsenic metabolism are more susceptible to the vascular effect of arsenic exposure.

Dietary intakes were measured by food frequency questionnaire, and therefore measurement errors are expected. Nondifferential measurement errors of nutrient intake (effect modifiers) may distort their modifying effect of the exposure-disease association (59). The absence of both alcohol drinking (due to religious beliefs) and a nutritional fortification program in the population strengthened the validity of dietary intakes measured by food frequency questionnaire. Although there were differences in the observed modifying effects of single nutrients, the heterogeneity was not apparent and may reflect differences in validity of the food frequency questionnaire in measuring different nutrients. We created a composite variable to capture the combined effects of all four nutrients. This method assumes equal contributions of the nutrients. Additional studies are needed to examine the role of each nutrient. In this regard, a recent study from our group showed that a large proportion of people in the study area had low levels of serum folate and vitamin B12 (60).

In conclusion, we found that arsenic exposure from drinking water, even at lower levels (<50 μg/liter and <100 μg/liter), was positively associated with high pulse pressure, and that the association was more apparent among those with lower intake levels of vitamins B2, B6, and B12 and folate. Future studies are needed to investigate the effect of low-level arsenic exposure from drinking water on specific atherosclerosis outcomes and cardiovascular diseases.

Abbreviations

    Abbreviations
     
  • CI

    confidence interval

  •  
  • DBP

    diastolic blood pressure

  •  
  • SBP

    systolic blood pressure

  •  
  • TWA

    time-weighted well arsenic concentration

The authors acknowledge support from grants P42ES10349, P30ES09089, R01CA107431, R01CA102484, and ES000260.

The authors would like to thank colleagues Dr. Lydia Zablotska and Dr. John Barron for their helpful comments.

Conflict of interest: none declared.

References

1.
Tseng
CH
Chong
CK
Chen
CJ
, et al. 
Dose-response relationship between peripheral vascular disease and ingested inorganic arsenic among residents in blackfoot disease endemic villages in Taiwan
Atherosclerosis
1996
, vol. 
120
 (pg. 
125
-
33
)
2.
Chen
CJ
Wu
MM
Lee
SS
, et al. 
Atherogenicity and carcinogenicity of high-arsenic artesian well water. Multiple risk factors and related malignant neoplasms of blackfoot disease
Arteriosclerosis
1988
, vol. 
8
 (pg. 
452
-
60
)
3.
Chen
CJ
Hsueh
YM
Lai
MS
, et al. 
Increased prevalence of hypertension and long-term arsenic exposure
Hypertension
1995
, vol. 
25
 (pg. 
53
-
60
)
4.
Rahman
M
Tondel
M
Ahmad
SA
, et al. 
Hypertension and arsenic exposure in Bangladesh
Hypertension
1999
, vol. 
33
 (pg. 
74
-
8
)
5.
Chen
CJ
Chiou
HY
Chiang
MH
, et al. 
Dose-response relationship between ischemic heart disease mortality and long-term arsenic exposure
Arterioscler Thromb Vasc Biol
1996
, vol. 
16
 (pg. 
504
-
10
)
6.
Tseng
CH
Chong
CK
Tseng
CP
, et al. 
Long-term arsenic exposure and ischemic heart disease in arseniasis-hyperendemic villages in Taiwan
Toxicol Lett
2003
, vol. 
137
 (pg. 
15
-
21
)
7.
Chiou
HY
Huang
WI
Su
CL
, et al. 
Dose-response relationship between prevalence of cerebrovascular disease and ingested inorganic arsenic
Stroke
1997
, vol. 
28
 (pg. 
1717
-
23
)
8.
Wang
CH
Jeng
JS
Yip
PK
, et al. 
Biological gradient between long-term arsenic exposure and carotid atherosclerosis
Circulation
2002
, vol. 
105
 (pg. 
1804
-
9
)
9.
Navas-Acien
A
Sharrett
AR
Silbergeld
EK
, et al. 
Arsenic exposure and cardiovascular disease: a systematic review of the epidemiologic evidence
Am J Epidemiol
2005
, vol. 
162
 (pg. 
1037
-
49
)
10.
British Geological Survey
Groundwater studies for arsenic contamination in Bangladesh (phase 1)
2006
Nottingham, United Kingdom
British Geological Survey
 
11.
Karagas
MR
Tosteson
TD
Morris
JS
, et al. 
Incidence of transitional cell carcinoma of the bladder and arsenic exposure in New Hampshire
Cancer Causes Control
2004
, vol. 
15
 (pg. 
465
-
72
)
12.
Ferreccio
C
Gonzalez
C
Milosavjlevic
V
, et al. 
Lung cancer and arsenic concentrations in drinking water in Chile
Epidemiology
2000
, vol. 
11
 (pg. 
673
-
9
)
13.
Lewington
S
Clarke
R
Qizilbash
N
, et al. 
Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies
Lancet
2002
, vol. 
360
 (pg. 
1903
-
13
)
14.
Rahman
M
Arsenic and hypertension in Bangladesh
Bull World Health Organ
2002
, vol. 
80
 pg. 
173
 
15.
Liu
L
Ikeda
K
Yamori
Y
Inverse relationship between urinary markers of animal protein intake and blood pressure in Chinese: results from the WHO Cardiovascular Diseases and Alimentary Comparison (CARDIAC) Study
Int J Epidemiol
2002
, vol. 
31
 (pg. 
227
-
33
)
16.
Pastor-Barriuso
R
Banegas
JR
Damian
J
, et al. 
Systolic blood pressure, diastolic blood pressure, and pulse pressure: an evaluation of their joint effect on mortality
Ann Intern Med
2003
, vol. 
139
 (pg. 
731
-
9
)
17.
Weitzman
D
Goldbourt
U
The significance of various blood pressure indices for long-term stroke, coronary heart disease, and all-cause mortality in men: the Israeli Ischemic Heart Disease Study
Stroke
2006
, vol. 
37
 (pg. 
358
-
63
)
18.
Pickering
TG
Hall
JE
Appel
LJ
, et al. 
Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research
Circulation
2005
, vol. 
111
 (pg. 
697
-
716
)
19.
Zakharyan
RA
Aposhian
HV
Arsenite methylation by methylvitamin B12 and glutathione does not require an enzyme
Toxicol Appl Pharmacol
1999
, vol. 
154
 (pg. 
287
-
91
)
20.
Gamble
MV
Liu
X
Ahsan
H
, et al. 
Folate, homocysteine, and arsenic metabolism in arsenic-exposed individuals in Bangladesh
Environ Health Perspect
2005
, vol. 
113
 (pg. 
1683
-
8
)
21.
Araki
A
Sako
Y
Fukushima
Y
, et al. 
Plasma sulfhydryl-containing amino acids in patients with cerebral infarction and in hypertensive subjects
Atherosclerosis
1989
, vol. 
79
 (pg. 
139
-
46
)
22.
Lim
U
Cassano
PA
Homocysteine and blood pressure in the Third National Health and Nutrition Examination Survey, 1988 –1994
Am J Epidemiol
2002
, vol. 
156
 (pg. 
1105
-
13
)
23.
Selhub
J
Folate, vitamin B12 and vitamin B6 and one carbon metabolism
J Nutr Health Aging
2002
, vol. 
6
 (pg. 
39
-
42
)
24.
Ahsan
H
Chen
Y
Parvez
F
, et al. 
Health Effects of Arsenic Longitudinal Study (HEALS): description of a multidisciplinary epidemiologic investigation
J Expo Sci Environ Epidemiol
2006
, vol. 
16
 (pg. 
191
-
205
)
25.
Parvez
F
Chen
Y
Argos
M
, et al. 
Prevalence of arsenic exposure from drinking water and awareness of its health risks in a Bangladeshi population: results from a large population-based study
Environ Health Perspect
2006
, vol. 
114
 (pg. 
355
-
9
)
26.
Chen
Y
Ahsan
H
Parvez
F
, et al. 
Validity of a food-frequency questionnaire for a large prospective cohort study in Bangladesh
Br J Nutr
2004
, vol. 
92
 (pg. 
851
-
9
)
27.
Nutrient Data Laboratory
USDA nutrient database for standard reference, release 15
2002
Beltsville, MD
Nutrient Data Laboratory, Agricultural Research Service, US Department of Agriculture
 
28.
Gopalan
C
Rama Sastri
BV
Balasubramanian
SC
Nutritive value of Indian foods
1989
Hyderabad, India
Indian Council of Medical Research, National Institute of Nutrition
29.
Willett
WC
Stampfer
MJ
Willett
WC
Implications of total energy intake for epidemiologic analyses
Nutritional epidemiology
1998
New York, NY
Oxford University Press
(pg. 
273
-
301
)
30.
O'Brien
E
Waeber
B
Parati
G
, et al. 
Blood pressure measuring devices: recommendations of the European Society of Hypertension
BMJ
2001
, vol. 
322
 (pg. 
531
-
6
)
31.
van Geen
A
Zheng
Y
Versteeg
R
, et al. 
Spatial variability of arsenic in 6000 tube wells in a 25 km2 area of Bangladesh
Water Resour Res
2003
, vol. 
39
 (pg. 
1140
-
51
)
32.
Steinmaus
CM
Yuan
Y
Smith
AH
The temporal stability of arsenic concentrations in well water in western Nevada
Environ Res
2005
, vol. 
99
 (pg. 
164
-
8
)
33.
Cheng
Z
van Geen
A
Seddique
AA
, et al. 
Limited temporal variability of arsenic concentrations in 20 wells monitored for 3 years in Araihazar, Bangladesh
Environ Sci Technol
2005
, vol. 
39
 (pg. 
4759
-
66
)
34.
Ahsan
H
Chen
Y
Parvez
F
, et al. 
Arsenic exposure from drinking water and risk of premalignant skin lesions in Bangladesh: baseline results from the Health Effects of Arsenic Longitudinal Study
Am J Epidemiol
2006
, vol. 
163
 (pg. 
1138
-
48
)
35.
Zeger
SL
Liang
KY
Longitudinal data analysis for discrete and continuous outcomes
Biometrics
1986
, vol. 
42
 (pg. 
121
-
30
)
36.
Sesso
HD
Stampfer
MJ
Rosner
B
, et al. 
Systolic and diastolic blood pressure, pulse pressure, and mean arterial pressure as predictors of cardiovascular disease risk in men
Hypertension
2000
, vol. 
36
 (pg. 
801
-
7
)
37.
Chen
Y
Graziano
JH
Parvez
F
, et al. 
Modification of risk of arsenic-induced skin lesions by sunlight exposure, smoking, and occupational exposures in Bangladesh
Epidemiology
2006
, vol. 
17
 (pg. 
459
-
67
)
38.
Poulter
NR
Independent effects of smoking on risk of hypertension: small, if present
J Hypertens
2002
, vol. 
20
 (pg. 
171
-
2
)
39.
Dart
AM
Kingwell
BA
Pulse pressure—a review of mechanisms and clinical relevance
J Am Coll Cardiol
2001
, vol. 
37
 (pg. 
975
-
84
)
40.
Safar
ME
Levy
BI
Struijker-Boudier
H
Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases
Circulation
2003
, vol. 
107
 (pg. 
2864
-
9
)
41.
Khattar
RS
Acharya
DU
Kinsey
C
, et al. 
Longitudinal association of ambulatory pulse pressure with left ventricular mass and vascular hypertrophy in essential hypertension
J Hypertens
1997
, vol. 
15
 (pg. 
737
-
43
)
42.
Zureik
M
Touboul
PJ
Bonithon-Kopp
C
, et al. 
Cross-sectional and 4-year longitudinal associations between brachial pulse pressure and common carotid intima-media thickness in a general population. The EVA Study
Stroke
1999
, vol. 
30
 (pg. 
550
-
5
)
43.
Domanski
M
Mitchell
G
Pfeffer
M
, et al. 
Pulse pressure and cardiovascular disease-related mortality: follow-up study of the Multiple Risk Factor Intervention Trial (MRFIT)
JAMA
2002
, vol. 
287
 (pg. 
2677
-
83
)
44.
Domanski
M
Norman
J
Wolz
M
, et al. 
Cardiovascular risk assessment using pulse pressure in the First National Health and Nutrition Examination Survey (NHANES I)
Hypertension
2001
, vol. 
38
 (pg. 
793
-
7
)
45.
Menotti
A
Lanti
M
Kafatos
A
, et al. 
The role of a baseline casual blood pressure measurement and of blood pressure changes in middle age in prediction of cardiovascular and all-cause mortality occurring late in life: a cross-cultural comparison among the European cohorts of the Seven Countries Study
J Hypertens
2004
, vol. 
22
 (pg. 
1683
-
90
)
46.
Barchowsky
A
Roussel
RR
Klei
LR
, et al. 
Low levels of arsenic trioxide stimulate proliferative signals in primary vascular cells without activating stress effector pathways
Toxicol Appl Pharmacol
1999
, vol. 
159
 (pg. 
65
-
75
)
47.
Barchowsky
A
Dudek
EJ
Treadwell
MD
, et al. 
Arsenic induces oxidant stress and NF-kappa B activation in cultured aortic endothelial cells
Free Radic Biol Med
1996
, vol. 
21
 (pg. 
783
-
90
)
48.
Lee
MY
Jung
BI
Chung
SM
, et al. 
Arsenic-induced dysfunction in relaxation of blood vessels
Environ Health Perspect
2003
, vol. 
111
 (pg. 
513
-
17
)
49.
Pi
J
Kumagai
Y
Sun
G
, et al. 
Decreased serum concentrations of nitric oxide metabolites among Chinese in an endemic area of chronic arsenic poisoning in inner Mongolia
Free Radic Biol Med
2000
, vol. 
28
 (pg. 
1137
-
42
)
50.
Willerson
JT
Ridker
PM
Inflammation as a cardiovascular risk factor
Circulation
2004
, vol. 
109
 (pg. 
II2
-
10
)
51.
Hsueh
YM
Cheng
GS
Wu
MM
, et al. 
Multiple risk factors associated with arsenic-induced skin cancer: effects of chronic liver disease and malnutritional status
Br J Cancer
1995
, vol. 
71
 (pg. 
109
-
14
)
52.
Zierold
KM
Knobeloch
L
Anderson
H
Prevalence of chronic diseases in adults exposed to arsenic-contaminated drinking water
Am J Public Health
2004
, vol. 
94
 (pg. 
1936
-
7
)
53.
Engel
RR
Smith
AH
Arsenic in drinking water and mortality from vascular disease: an ecologic analysis in 30 counties in the United States
Arch Environ Health
1994
, vol. 
49
 (pg. 
418
-
27
)
54.
Lewis
DR
Southwick
JW
Ouellet-Hellstrom
R
, et al. 
Drinking water arsenic in Utah: a cohort mortality study
Environ Health Perspect
1999
, vol. 
107
 (pg. 
359
-
65
)
55.
Soucy
NV
Ihnat
MA
Kamat
CD
, et al. 
Arsenic stimulates angiogenesis and tumorigenesis in vivo
Toxicol Sci
2003
, vol. 
76
 (pg. 
271
-
9
)
56.
Forman
JP
Rimm
EB
Stampfer
MJ
, et al. 
Folate intake and the risk of incident hypertension among US women
JAMA
2005
, vol. 
293
 (pg. 
320
-
9
)
57.
Eikelboom
JW
Lonn
E
Genest
J
Jr
, et al. 
Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence
Ann Intern Med
1999
, vol. 
131
 (pg. 
363
-
75
)
58.
Wilcken
DE
Wilcken
B
B vitamins and homocysteine in cardiovascular disease and aging
Ann N Y Acad Sci
1998
, vol. 
854
 (pg. 
361
-
70
)
59.
Greenland
S
The effect of misclassification in the presence of covariates
Am J Epidemiol
1980
, vol. 
112
 (pg. 
564
-
9
)
60.
Gamble
MV
Ahsan
H
Liu
X
, et al. 
Folate and cobalamin deficiencies and hyperhomocysteinemia in Bangladesh
Am J Clin Nutr
2005
, vol. 
81
 (pg. 
1372
-
7
)